Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -9.50% | -- |
| Total Revenue | -- | -- | -- | -9.50% | -- |
| Cost of Revenue | 34.84% | -14.64% | -38.45% | 27.99% | 133.22% |
| Gross Profit | 1,216.73% | 47.21% | 38.45% | -28.46% | -133.64% |
| SG&A Expenses | 17.67% | 4.42% | -29.95% | -28.66% | -60.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.49% | -8.93% | -34.75% | -26.50% | -58.49% |
| Operating Income | 600.13% | 23.80% | 34.75% | 26.23% | 58.81% |
| Income Before Tax | 504.84% | 57.91% | 82.99% | 50.73% | 47.81% |
| Income Tax Expenses | -595.12% | 133.33% | -279.89% | 76.86% | 147.26% |
| Earnings from Continuing Operations | 505.39% | 57.33% | 85.29% | 50.56% | 47.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 505.39% | 57.33% | 85.29% | 50.56% | 47.15% |
| EBIT | 600.13% | 23.80% | 34.75% | 26.23% | 58.81% |
| EBITDA | 644.74% | 24.72% | 35.83% | 27.10% | 60.61% |
| EPS Basic | 331.35% | 76.78% | 91.89% | 57.58% | -85,712.12% |
| Normalized Basic EPS | 331.03% | 77.09% | 91.30% | 40.00% | -87,875.00% |
| EPS Diluted | 331.30% | 76.78% | 91.89% | 57.58% | -85,712.12% |
| Normalized Diluted EPS | 331.03% | 77.09% | 91.30% | 40.00% | -87,875.00% |
| Average Basic Shares Outstanding | 75.24% | 83.74% | 87.71% | 18.96% | -99.94% |
| Average Diluted Shares Outstanding | 75.24% | 83.74% | 87.71% | 18.96% | -99.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |